Our AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.
Small Molecules can permeate cells but can't bind complex targets and
biologics, such as antibodies, can only act on targets displayed outside of cells.
Macrocycles, which are found in nature, bridge the gap between small molecules and biologics by transcending the traditional boundaries of cell permeability to access deep, complex targets with high specificity.
We’re a California-based biotech company using our AI-enhanced macrocyclic technology to transform undruggable targets into de novo drugs that change the future of medicine.
Our founders are scientists from the University of California Santa Cruz who have worked with both pharma and academia to develop macrocycle programs.
Crafting code. Manipulating medchem. Conquering mountains in life and in the lab.Contact Us